



Altmetric Data – What can it Mean for You?

December 9th, 2015

Ben McLeish,
Product Sales Manager, Europe

ben@altmetric.com

What we'll cover

- Definition of altmetrics
- Why altmetrics; why now?
- Why altmetrics matter to Pharma
- Who we are – where you see our data
- How we do it & What we track
- Examples and Demo

What are altmetrics? In the broadest sense they measure...

- Attention
- Immediacy (snapshot NOT time lapse)
- Non-academic engagement
 - Beyond scholarly academic publishing
- Non-traditional sources
 - Beyond academic journals
- Non-traditional research outputs
 - Provide data for all outputs, not just research articles (code, data, software, images, etc)




What are they not?

- Web analytics
 - Searches/sessions/platform performance
- Quality indicators
 - Kim Kardashian versus Nelson Mandela
- Proxies/predictors for citations
- Social media monitoring
 - Hootsuite, etc
- Media media monitoring
 - Cision, Meltwater, etc..


What do they indicate? Attention/engagement on a *spectrum*

- Superficial
- Article may or may not have been read
- Many potential readers but few actual
- Cost-light (er)




- Article more likely to be read
- Cost-heavy (ier)
- Readers = practitioners (?)
- Actionable (?)

What *audiences* are they indicators for?



In a nutshell? Altmetrics are...

QUALITATIVE!





Why altmetrics and why ***now***?



@BenMcLeish
@altmetric

Digitally native research is openly available...**Everyone**, not just researchers, **can read research...and talk about it**




Source: Altmetric internal data, November 2015



@BenMcLeish
@altmetric

Democratization of information: **Everyone** can read peer-reviewed research



Print based paradigm in a digital age: *Lagging indicators*

Article metrics for:

The evolution of cichlid fish egg-spots is linked with a *cis*-regulatory change

M. Emilia Santos, Ingo Braasch, Nicolas Boileau, Britta S. Meyer, Loïc Sauter, Astrid Böhne, Heinz-Georg Belting, Markus Affolter & Walter Salzburger


Nature Communications 5, Article number: 5149 (2014) | doi:10.1038/ncomms6149

Last updated: 14 October 2014 13:45:47 EDT

Total citations



Online attention



This Altmetric score means that the article is:

- in the 99 percentile (ranked 281st) of the 38,911 tracked articles of a similar age in all journals



The cichlids egg-spots: How evolution creates new characteristics

Daily News


The evolution of new traits with novel functions has normally posed a challenge to evolutionary biology. Studying the colour mar ...

2014-10-09T10:17:50+01:00



@RouhiRoo
@altmetric

Traditional metrics = scholarly use



Why altmetrics should matter to *pharma*



Altmetric

A sector with unique needs

BMJ

Keep up-to-speed with the latest papers from all our specialty journals
To sign up for table of contents alerts [click here](#)



Close x

BMJ Open

Search this site

[Advanced search](#)

An open access, online-only general medical journal dedicated to publishing research from all disciplines and therapeutic areas

[Latest content](#)

[Archive](#)

[Browse by topic](#)

[About the journal](#)

[Submit a paper](#)

[Jobs](#)

[Help](#)

[Latest content](#)

[Archive](#)

[eLetters](#)

[RSS](#)

[Home](#) > [Volume 5, Issue 11](#) > [Article](#)

[RSS](#)

BMJ Open 2015;5:e009758 doi:10.1136/bmjopen-2015-009758

Ethics

Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012

Jennifer E Miller¹, David Korn², Joseph S Ross^{3,4,5}

[+ Author Affiliations](#)

Correspondence to

Dr Jennifer E Miller; jennifer.miller@nyumc.org

This Article

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [Previous versions](#)
- [Review history](#)
- [Supplementary Data](#)

Services

- [Email this link to a friend](#)
- [Alert me when this article is cited](#)
- [Alert me if a correction is posted](#)
- [Alert me when eletters are published](#)

220
Picked up by **3** news outlets
Blogged by **1**
Tweeted by **246**
Mentioned in **2** Google+ posts
[Click for more details](#)

Remember me.

[Forgot your sign in details?](#)

[Login via OpenAthens](#)

[Login via your home organisation](#)

[Recommend to your Institution](#)

[Register to receive email alerts](#)



How can we help?

Who are we?

Altmetric is a **data science company** that **tracks attention** to research outputs, delivering **output level metrics** via visually engaging, intuitive interfaces.



@RouhiRoo
@altmetric

Where will you see our data? **Publishers**



ELSEVIER

WILEY



M MICHIGAN PUBLISHING
UNIVERSITY OF MICHIGAN PRESS



THE COCHRANE
COLLABORATION®



Wolters Kluwer
Health



nature publishing group **npg**



Taylor & Francis
Taylor & Francis Group



Springer



THE NATIONAL ACADEMIES PRESS



Altmetric

Institutions: reputation management, fundraising, funding evaluation/ compliance



MAX-PLANCK-GESELLSCHAFT




Centers for Disease Control and Prevention
CDC 24/7: Saving Lives. Protecting People™



Where will you see our data? **Other metrics providers**



Scopus



@RouhiRoo
@altmetric

Where will you see our data? **Platforms**



Recommendation Engine
Integration for Medical research
Apps



Integrating Altmetric service into
publishing platform




Altmetric Integration for JAMA and
others to monitor research impact



Integrates Altmetric data for over 1
million articles



Where will you see our data? **Books**



THE NATIONAL RESEARCH COUNCIL ON

The Growth of **INCARCERATION** in the United States

Exploring Causes and Consequences

NATIONAL RESEARCH COUNCIL ON THE PENITENTIARY SYSTEM

Status: Final Book
Downloads: 10,785

Overview Conte

Total PDF Downloads: 10,785

PDF Downloads Over Time

Export




Total Downloads

Date

NAP.edu

PDF Downloads by Country

Export




+

-

1 10 100 1k 10k 100k

NAP.edu

Altmetric Score



443

Mentioned by:

- 5 news outlets
- 9 blogs
- 450 tweeters
- 9 Facebook posts

What is an Altmetric score?

Altmetric calculates a score based on the online attention a publication receives. Each colored thread in the circle represents a different type of online attention and the number in the center is the Altmetric score. The score is calculated based on two main sources of online attention: social media and mainstream news media. Older publications will typically score higher because they have had more time to get noticed.

For a more detailed description of Altmetric, the Altmetric score, and sources used, please see [Altmetric's information page](#).

Altmetrics are about *reach*: A robust strategy can...

- Help identify optimal user/platform targeting
- Help you understand segments of attention
 - Regions
 - Therapeutic areas
 - Practitioners, etc
- Mitigate PR crises/fires
- Identify new journals, communities, audiences, practitioners, target outlets
- Identify pockets of misinformation

So how do we do it?

The Altmetric database:
Tracking 4.5M articles and growing

How do we populate our database? **3 things needed**

An ***output***
(journal
article,
dataset, etc)

An ***identifier***
attached to
the output
(DOI, NCT,
PubMed etc)

Mentions in
a ***source we
track***



Sources we track...**MORE** than social media

News outlets

- Over 1,300 sites and growing every day
- Manually curated list
- Text mining
- Global coverage

Academic blogs and social media

- Twitter, Facebook, Google+
- Public posts only
- Manually curated list
- Almost 10K academic/field specific blogs

Post-publication peer review

- Publons
- PubPeer

Reference managers

- Mendeley, CiteULike
- Reader counts

Other sources

- Wikipedia
- YouTube
- Reddit
- F1000
- Pinterest
- Q&A
- Citations (by end of 2015)

Policy documents

- NICE Evidence
- Intergovernmental Panel on Climate Change
- Many more...

Unique IDs we track...**MORE** than DOIs



DOIs

General

PubMed ID

Health Sciences

arXiv ID

Physics, Mathematics &
Computer Sciences

ADS ID

Astrophysics data system

SSRN ID

Social Sciences

RePEC ID

Economics

Handles


General

ClinicalTrials.gov
Records

Medicine/biomedical

Visuals we provide...**More** than just numbers

Volume	Sources	Authors
The score for an article rises as more people mention it.	Each source category contributes a different base amount to the final score.	Assess the author of each mention in terms of their reach, promiscuity and bias.



A sector with unique needs

ClinicalTrials.gov

A service of the U.S. National Institutes of Health

Find Studies ▾ About Clinical Studies ▾ Submit Studies ▾ Resources ▾ About This Site ▾

Home > Find Studies > Study Record Detail

Blood-Brain Barrier Disruption Usir

This study is currently recruiting participants

Verified March 2015 by InSightec

Sponsor:
InSightec

Information provided by (Responsible Party):
InSightec

Full Text View

Tabular View

No

▶ Purpose

The purpose of this study is to evaluate the safety and efficacy of the accumulation of doxorubicin in brain tumours and as a basis for later studies to evaluate its clinical efficacy.

Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound

Overview of attention for clinical trial study record



About this score

In the top 5% of all research outputs scored by Altmetric

MORE...

Mentioned by

4 news outlets
7 blogs
2 tweeters

What is this page?

SUMMARY

News

Blogs

Twitter

So far, Altmetric has seen 7 posts from 7 blogs.

Blood-Brain Barrier Opened Non-Invasively With Focused...

Neuroscience, 06 Dec 2015

Blood-Brain Barrier Opened Non-Invasively With Focused Ultrasound for the First TimeThe blood-brain barrier has been non-invasive...

Blood-brain barrier opened non-invasively for the first time in humans

3quarksdaily, 11 Nov 2015

From KurzweilAI: The blood-brain barrier has been non-invasively opened in a human patient for the first time. A team at...

Scientists Have Breached The Blood-Brain Barrier For The First Time And Treated A Brain Tumor Using An "Ultrasonic Screwdriver"

IFLScience - The Brain, 10 Nov 2015

The...

Blood-brain Barrier Opened Non-invasively for First Time

Laboratory Equipment News, 09 Nov 2015

The blood-brain barrier has been non-invasively opened in a patient for the first time. A team at Sunnybrook Health Sciences...

Altmetric Data is Now Available

Altmetric.com, 12 Nov 2015

Explore attention data for more than 10...

Blood-brain barrier opened non-invasively for first time in humans

KurzweilAI, 11 Nov 2015

Opening up the blood-brain barrier to drug delivery has been non...

Accessing the Blood Brain Barrier

Pharmaceutical Intelligence, 09 Nov 2015

Accessing the Blood Brain Barrier for Chemotherapy: The Blood-Brain Barrier Opened...



A sector with unique needs

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Find Studies | About Clinical Studies | Submit Studies | Resources | About This Site

Home > Find Studies > Study Record Detail

Confirmatory Study of Eteplirsen in

This study is currently recruiting participants
Verified September 2015 by Sarepta Therapeutics

Sponsor:
Sarepta Therapeutics

Information provided by (Responsible Party):
Sarepta Therapeutics

Full Text View | Tabular View | No S

Confirmatory Study of Eteplirsen in DMD Patients (PROMOVI)

Overview of attention for clinical trial study record

79

Altmetric score: In the top 5% of all research outputs scored by Altmetric

Mentioned by:

- 2 blogs
- 68 tweeters
- 16 Facebook pages
- 1 Wikipedia page

Wikipedia: **Eteplirsen**
Cited by user JonMoulton on 03 Oct 2014
Duchenne muscular dystrophy is caused when a mutation in the DMD gene changes t... due to a...



Data we provide...**MORE** than just numbers; *auditable data*



About this score

In the top 5% of all research outputs scored by Altmetric

MORE...

Mentioned by

- 2 news outlets
- 1 blog
- 9 tweeters
- 1 Facebook page

Tools

Open in a new tab

SUMMARY

News

Blogs

Twitter

Facebook

So far, Altmetric has seen 9 tweets from 9 users, with an upper bound of 76,394 followers.



Edoardo Melilli

@EdoardoMelilli

RT @hswapnil: Other #PCSK9 trials: SPIRE <https://t.co/3w7cEJ8d9R> ODYSSEY OUTCOMES <https://t.co/QckFNXRxkg> #kidneywk

06 Nov 2015



Swapnil Hiremath, MD

@hswapnil

Other #PCSK9 trials: SPIRE <https://t.co/3w7cEJ8d9R> ODYSSEY OUTCOMES <https://t.co/QckFNXRxkg> #kidneywk

06 Nov 2015



Mad_Scientist

@Mad_Scientist2

@matthewherper @Salamanos_dog <https://t.co/XfaehWD1aZ> Est. enrollment 18000 <https://t.co/SIcATheefg> Est enrollment 17000. What am I missing?

09 Jun 2015



John LaMattina

@John_LaMattina

@matthewherper What do you mean "force"? All 3 due in 2018 <https://t.co/TB0Y371Cxr> <https://t.co/WAuoWlg1O6> <https://t.co/IEmlnuxtIR>

08 Jun 2015



Ethan Weiss

@ethanjweiss

@matthewherper What do you mean "force"? All 3 due in 2018 <https://t.co/TB0Y371Cxr> <https://t.co/WAuoWlg1O6> <https://t.co/IEmlnuxtIR>



Matthew Herper

@matthewherper

@adamjshay @jonathanrockoff @John_LaMattina @ethanjweiss PFE <http://t.co/3uee1wODEq> SNY <http://t.co/tOO6QrV1rW> AMGN <http://t.co/6bB2F5Dq4Y>

Using the Altmetric database

Explorer for Institutions

- Reporting from article level to entire organization
 - Therapeutic area? Drug? Region? Phase?
- Visualizations/alerts
- *Access to full Altmetric database*
 - ~4.5M+ articles including competitor data
- Easy implementation; little reliance on researcher maintenance
- Custom reporting
- Access to complete Altmetric database (not just your/your firm/company's data)

Competitive benchmarking: Altmetric database retains data for 4.5M+ growing

Altmetric Explorer My workspaces Explore the data Media monitoring Groups management Explore my institution Help Logged in as sara@altmetric.com

Articles mentioned at least once in the past 1m

Pick new articles: Summary report Articles Activity Journals Save this workspace API

You've chosen to search the entire Altmetric database.

Or choose a person, subject or department

- Mentioned in the past
- With keyword
- In these journals
- With identifiers
- From publisher
- With handle prefix
- With Medline subjects
- With subjects
- Matching PubMed query
- Funded by
- Mentioned at any time on
- Order by

All mentions	931,686	News	37,952	Blogs	16,846	Policy documents	191	Peer reviews	1,090	Twitter	846,626
Facebook	4,204	Wikipedia	11,381	Google+	9,908	Reddit	2,896	Research highlights	457	Video	73
Q&A	62										

Chart of mentions of 205,821 matched articles from 22nd October 2015 to 21st November 2015

Location of Twitter users

Ranking	Country	Percentage
1	US	32 %
2	UK	22 %
3	AU	7 %

Integrated PubMed Advanced Search

> With Medline subjects

> With subjects

▼ Matching PubMed query

3 results fetched from PubMed, 3 matched when no time filter applied.

> Funded by



MT-45, a new psychoactive substance associated with hearing loss and unconsciousness.
Clinical Toxicology (15563650)



Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45.
Clinical Toxicology (15563650)



MT-45: a new, dangerous legal high.
Journal of Opioid Management

Competitive benchmarking: Filter by Pubmed query for "Alirocumab"

Articles with the selected PubMed query mentioned at least once in the past 6m

Pick new articles: You've chosen to search the entire Altmetric database. Or choose a person, subject or department

▼ Mentioned in the past

- 1 day
- 3 days
- 1 week
- 1 month
- 3 months
- 6 months
- 1 year
- Any time

► With keyword

► In these journals

► With identifiers

► From publisher

► With handle prefix

► With Medline subjects

Summary report Articles Activity Journals

Export journals Save this workspace API

Scores Article timelines

Articles	Score			Articles in past 1y	Journal
	6m Total	Total	Median		
6	237	663	35.76		New England Journal of Medicine Add to filters
1	25	25	25.25		European Heart Journal Add to filters
1	15	15	15		Nature Reviews Cardiology Add to filters
1	15	15	14.85		JAMA: Journal of the American Medical Association Add to filters
1	6	6	6.2		BMC Medicine Add to filters
1	6	6	5.9		Vascular Health and Risk Management Add to filters
1	5	5	5.2		Expert Opinion on Drug Metabolism & Toxicology Add to filters
1	5	5	4.8		Circulation: Cardiovascular Genetics Add to filters
1	3	3	3		Journal of the American College of Cardiology (JACC) Add to filters
1	3	4	3		Trends in Cardiovascular Medicine Add to filters
1	3	8	3		mAbs Add to filters
1	3	8	3		Current Atherosclerosis Reports Add to filters

https://twitter.com/drtom_butler

Competitive benchmarking: Filter by Pubmed query for "Alirocumab"

Articles with the selected PubMed query mentioned at least once in the past 6m

Pick new articles: You've chosen to search the entire Altmetric database. Or choose a person, subject or department

▼ Mentioned in the past

- 1 day
- 3 days
- 1 week
- 1 month
- 3 months
- 6 months
- 1 year
- Any time

► With keyword

► In these journals

► With identifiers

► From publisher

► With handle prefix

► With Medline subjects

Summary report Articles Activity Journals

Export journals Save this workspace API

Scores Article timelines

Articles	Score			Articles in past 1y	Journal
	6m Total	Total	Median		
6	237	663	35.76		New England Journal of Medicine Add to filters
1	25	25	25.25		European Heart Journal Add to filters
1	15	15	15		Nature Reviews Cardiology Add to filters
1	15	15	14.85		JAMA: Journal of the American Medical Association Add to filters
1	6	6	6.2		BMC Medicine Add to filters
1	6	6	5.9		Vascular Health and Risk Management Add to filters
1	5	5	5.2		Expert Opinion on Drug Metabolism & Toxicology Add to filters
1	5	5	4.8		Circulation: Cardiovascular Genetics Add to filters
1	3	3	3		Journal of the American College of Cardiology (JACC) Add to filters
1	3	4	3		Trends in Cardiovascular Medicine Add to filters
1	3	8	3		mAbs Add to filters
1	3	8	3		Current Atherosclerosis Reports Add to filters

https://twitter.com/drtom_butler

Comparing Publicly-funded vs Industry-funded trials

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Example: "Heart attack" AND "Los Angeles"
Search for studies:

[Advanced Search](#) | [Help](#) | [Studies by Topic](#) | [Glossary](#)

[Find Studies](#) | [About Clinical Studies](#) | [Submit Studies](#) | [Resources](#) | [About This Site](#)

Home > Find Studies > Advanced Search Text Size ▾

Advanced Search

Fill in any or all of the fields below. Click on the label to the left of each search field for more information or read the [Help](#)

Search Terms: [Help](#)

Additional Criteria

Gender: ▾

Age Group: Child (birth–17)
 Adult (18–65)
 Senior (66+)

Phase: Phase 0 Phase 1 Phase 2
 Phase 3 Phase 4

Funder Type: NIH Other U.S. Federal agency
 Industry All others (individuals, universities, organizations)

Safety Issue: Has an Outcome Measure designated as a safety issue

First Received: From To (MM/DD/YYYY)

Last Updated: From To (MM/DD/YYYY)

[Help](#)

Additional Criteria

Gender: ▾

Age Group: Child (birth–17)
 Adult (18–65)
 Senior (66+)

Phase: Phase 0 Phase 1 Phase 2
 Phase 3 Phase 4

Funder Type: NIH Other U.S. Federal agency
 Industry All others (individuals, universities, organizations)

Safety Issue: Has an Outcome Measure designated as a safety issue

First Received: From To (MM/DD/YYYY)

Last Updated: From To (MM/DD/YYYY)

[Help](#)

Reg.Compliance: Tracking ClinicalTrials.gov NCT records

Rank	NCT Number	Title	Recruitment	Study Result	Conditions	Intervention	Sponsor/Coll	Gender
	NCT0173308	The Mycoph...	Recruiting	No Results A	Heart Transplantation, Kid		Genentech, I	Female
	NCT0174410	Multicente	Recruiting	No Results A	Nasal Conge	Drug: pseudo	Perrigo Com	Both
	NCT0259425	Phase 2 Stud	Recruiting	No Results A	Dental Caries	Drug: C16G2	C3 Jian, Inc.	Both
	NCT0258615	Effect of RVX	Recruiting	No Results A	Diabetes Me	Drug: RVX00	Resverlogix C	Both
	NCT0257263	Phase I Stu	Recruiting	No Results A	Pneumococc	Biological: Pr	ImmunoBio	Both
	NCT0190559	Phase III Tr	Recruiting	No Results A	Carcinoma o	Drug: nirapa	Tesaro, Inc.	Both
	NCT0146047	mmunother	Recruiting	No Results A	NSCLC Lung	Biological: Ra	Recombio SL	Both
	NCT0261606	Comparative	Recruiting	No Results A	Trauma Pair	Drug: Transd	Daiichi Sanky	Both
	NCT0261352	safety and In	Not yet recr	No Results A	Malaria	Biological: Pf	Sanaria Inc.	Both
1	NCT0259632	Study Inve	Recruiting	No Results A	Allergy Asth	Drug: Mitiza	Abbott Linic	Both
1	NCT0257894	Luciclovine (Not yet recr	No Results A	Cancer of the	Radiation: Fl	Blue Earth D	Male
1	NCT0254415	valuation of	Recruiting	No Results A	Irritable Bow	Drug: Lubipr	Sucampo AG	Both
1	NCT0254200	safety and Ef	Recruiting	No Results A	Coronary Art	Device: Orbu	OrbusNeich	Both
1	NCT0250068	The Safety, T	Recruiting	No Results A	Influenza, Hu	Biological: M	Nova Immun	Both
1	NCT0249584	Study of U	Recruiting	No Results A	Highly Drug-i	Drug: UCB09	UCB Biophar	Both
1	NCT0249143	Randomize	Recruiting	No Results A	Female Infer	Drug: Dydrog	Abbott PRA	Female
1	NCT0248693	Long Term	Recruiting	No Results A	Rheumatoid	Drug: CHS-02	Coherus Bios	Both
1	NCT0240104	Multi-Cent	Recruiting	No Results A	Diffuse Large	Drug: Ibrutin	Pharmacyclic	Both
1	NCT0239193	Study of In	Recruiting	No Results A	Intrinsic Agin	Drug: RCS-01	RepliCel Life	Both
2	NCT0238527	Study Compa	Recruiting	No Results A	Coronary Ste	Device: MiSt	ECRI bv Mic	Both
2	NCT0234990	treosulfan-b	Recruiting	No Results A	Primary Imm	Drug: Treosu	medac Gmb	Both
2	NCT0234938	Maintaining	Recruiting	No Results A	Cancer of the	Drug: BHR-20	BHR Pharma	Male
2	NCT0233305	treosulfan-b	Recruiting	No Results A	Acute Lymph	Drug: Treosu	medac Gmb	Both
2	NCT0233014	safety and Ef	Recruiting	No Results A	Tendinosis T	Drug: RCT-01	RepliCel Life	Both
2	NCT0231870	DS-5565 Pha	Recruiting	No Results A	Diabetic Peri	Drug: DS-556	Daiichi Sanky	Both
2	NCT0229815	Study of At	Recruiting	No Results A	Non-small Ce	Drug: atezoli	Incyte Corpo	Both
2	NCT0229769	Phase II Trial	Recruiting	No Results A	Breast Canc	Biological: N	Cancer Insig	Both
3	NCT0229628	safety and Ef	Not yet recr	No Results A	Radiation Pn	Drug: Pirfeni	Beijing Conti	Both
2	NCT0227952	A Clinical Tri	Recruiting	No Results A	Fatty Liver	Drug: Aramc	Galmed Phar	Both
3	NCT0227372	valuation of	Recruiting	No Results A	CKD Anemia	Drug: Epoeti	FibroGen As	Both
3	NCT0226804	Study of RTX	Recruiting	No Results A	Diffuse Large	Biological: R1	mAbxience S	Both
3	NCT0226466	Observation	Recruiting	No Results A	Pancreatic N	Drug: sunitin	Pfizer Novar	Both
3	NCT0217859	Open-label S	Recruiting	No Results A	Infection, Hu	Drug: DTG 50	ViiV Healthc	Both
3	NCT0214922	APVAC Pha	Recruiting	No Results A	Glioblastoma	Drug: APVAC	immatics Bio	Both
3	NCT0213813	long-term Se	Recruiting	No Results A	Constipation	Drug: Lubipr	Sucampo AG	Both
3	NCT0212730	Phase 4 Stud	Recruiting	No Results A	Heart Failure (HF)		GE Healthcar	Both
3	NCT0207716	ibrutinib in C	Recruiting	No Results A	Relapsed Dif	Drug: Ibrutin	Pharmacyclic	Both
3	NCT0207243	doxaban vs.	Recruiting	No Results A	Atrial Fibrilla	Drug: edoxat	Daiichi Sanky	Both
3	NCT0205231	safety and Ef	Recruiting	No Results A	Anemia in In	Drug: FG-459	FibroGen As	Both
4	NCT0204218	fficacy and	Recruiting	No Results A	Constipation	Drug: Lubipr	Sucampo AG	Both

Authors	Departments	Journal subjects	Custom groups
My custom groups			
<input type="button" value="Add a new article group"/>			
ARTICLE LIST	4000 NCT Numbers	3,965 articles	151 mentioned <input type="button" value="Edit"/> <input type="button" value="Delete"/>
ARTICLE LIST	Article Set from 10/03/2015 at 10:37	523 articles	137 mentioned <input type="button" value="Edit"/> <input type="button" value="Delete"/>
ARTICLE LIST	Article Set from 11/10/2014 at 23:03	-	mentioned <input type="button" value="Edit"/> <input type="button" value="Delete"/>
ARTICLE LIST	Author 1 Outputs for this guy	-	mentioned 1,049 <input type="button" value="Edit"/> <input type="button" value="Delete"/>
ARTICLE LIST	Author 1	-	mentioned 120 <input type="button" value="Edit"/> <input type="button" value="Delete"/>
ARTICLE LIST	BB 2012-2015	-	mentioned 397 <input type="button" value="Edit"/> <input type="button" value="Delete"/>

Edit group article list ✕

Enter a list of up to 10,000 DOIs, arXiv IDs, RePEc identifiers, handles or PubMed IDs corresponding to the articles you are interested in below. Each one should be on a separate line.

NCT01733082

NCT01744106

NCT02594254

NCT02586155

NCT02572635

NCT01905592

NCT01460472

NCT02616068


NCT02613520

NCT02596321

NCT02578940

NCT02544152

Competitive analysis: Custom reporting/alerts



Altmetric Explorer summary report for:
Alerts on Industry-funded Trials

2,053
total articles

8,791
distinct mentions

8,489
score of first 1k articles

Top articles

Score	Article
106	Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Severe-to-profound Hearing Loss ClinicalTrials.gov
89	Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7) ClinicalTrials.gov
83	An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) ClinicalTrials.gov
78	Confirmatory Study of Eteplirsen in DMD Patients (PROMISD) ClinicalTrials.gov
76	International EXPAND Heart Pivotal Trial (EXPANDHeart) ClinicalTrials.gov

news, blogs, policy

<input checked="" type="checkbox"/> None	Daily	Weekly	To Excel
<input checked="" type="checkbox"/> None	Daily	Weekly	To Excel
<input checked="" type="checkbox"/> None	Daily	Weekly	To Excel
<input checked="" type="checkbox"/> None	Daily	Weekly	To Excel
<input checked="" type="checkbox"/> None	Daily	Weekly	To Excel
<input checked="" type="checkbox"/> None	Daily	Weekly	To Excel

Total score	Articles	Journal
9,136	2,053	ClinicalTrials.gov

[Go to reports](#)

Sources of attention paid to top 1k articles

Mentions in timeframe	Count
Twitter	6,948
Blogs	116
Traditional media	659
Facebook	916
Google+	79

[Go to reports](#)



Thanks!

(Questions?)

Ben@altmetric.com

@BenMcLeish